<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Finding Dopa – Parkinson’s Disease Research and Clinical Trials</title>
  <meta name="description" content="Explore the latest in Parkinson’s disease research, treatments, and clinical trials. Finding Dopa offers resources and hope for a cure.">
  <link rel="icon" href="/favicon.png" type="image/png">
  <link rel="apple-touch-icon" href="/favicon.png">
  <meta name="theme-color" content="#000000">
  <link href="https://fonts.googleapis.com/css2?family=Orbitron:wght@400;700&family=PT+Serif:wght@700&display=swap" rel="stylesheet">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.5.0/css/all.min.css">
  <style>
    html, body {
      margin: 0;
      padding: 0;
      font-family: 'PT Serif', serif;
      color: #222;
      background: radial-gradient(ellipse at top, #0b0f1a, #000);
      overscroll-behavior: none;
      overflow-x: hidden;
    }

    body {
      display: flex;
      flex-direction: column;
      min-height: 100vh;
    }

    header {
      background-color: #1a1a1a;
    }

    .main-content {
  max-width: 700px;
  margin: 0 auto;
  padding: 0 20px;
  box-sizing: border-box;
}

    .top-bar {
      display: flex;
      align-items: center;
      background: #1a1a1a;
      padding: 10px;
      flex-wrap: wrap;
    }

    .home-brand {
      display: flex;
      align-items: center;
      gap: 8px;
      text-decoration: none;
      color: #007acc;
      font-size: 1.2rem;
      margin-right: 15px;
    }

    .logo-text {
      font-family: 'PT Serif', serif;
      font-weight: 700;
      font-size: 1.4rem;
      color: white;
    }

    .slider-container {
      width: 100%;
      display: flex;
      gap: 10px;
      padding: 10px;
      overflow-x: auto;
      scrollbar-width: none;
    }

    .slider-container::-webkit-scrollbar {
      display: none;
    }

    .slide {
      flex: 0 0 auto;
      background: #1f1f1f;
      color: white;
      text-decoration: none;
      padding: 8px 15px;
      border-radius: 8px;
      white-space: nowrap;
      font-size: 0.95rem;
    }

    .slide-link {
      color: white;
      text-decoration: none;
      display: block;
    }

    .slide-link:hover {
      color: #00bfff;
    }

    .slide.active {
      background: #fdfdfd;
      color: #2e2a89;
      border: 2px solid #2e2a89;
    }
    
    h1, h2, h3, .hero-line, .cta-button {
      font-family: 'Orbitron', sans-serif;
      text-transform: uppercase;
      letter-spacing: 0.05em;
      color: #00f7ff;
      text-shadow: 0 0 5px #00f7ff, 0 0 10px #00f7ff;
    }

    p, .hero-line {
      color: white;
      text-shadow: 0 0 5px #A576E0, 0 0 10px #A576E0;
    }

/*color: #A576E0;*/
    
    .cta-button {
      background: #ff00c8;
      color: white;
      padding: 0.8rem 1.8rem;
      text-decoration: none;
      border-radius: 8px;
      font-weight: bold;
      font-size: 1.1rem;
      transition: all 0.3s ease;
      box-shadow: 0 0 5px #ff00c8, 0 0 10px #ff00c8;
    }

    .cta-button:hover {
      background: #880088;
      transform: translateY(-3px) scale(1.05);
      box-shadow: 0 0 10px #ff00c8, 0 0 20px #ff00c8;
    }

    .hero-section {
  max-width: 700px;
  margin: 0 auto;
  padding: 20px 0;
  text-align: center;
  background: radial-gradient(ellipse at top, #0b0f1a, #000);
}

    .hero-img {
      max-width: 100%;
      height: auto;
      border-radius: 12px;
    }

    #main {
      padding: 20px 0;
      color: #e0e0e0;
      display: grid;
      gap: 20px;
    }

    .intro {
      text-align: center;
    }

    .intro h2 {
      font-size: 2.5rem;
      margin-bottom: 10px;
      color: #b2fefa;
    }

    .tagline {
      font-size: 1.2rem;
      color: #aaa;
    }

    .science-block {
      background: rgba(255, 255, 255, 0.05);
      padding: 15px;
      border-radius: 12px;
      border: 1px solid rgba(0, 255, 255, 0.2);
      transition: transform 0.3s ease;
    }

    .science-block:hover {
      transform: translateY(-5px);
    }

    .science-block h3 {
      font-size: 1.8rem;
      margin-bottom: 15px;
      position: relative;
    }

    .science-block h3::after {
      content: '';
      display: block;
      width: 50px;
      height: 3px;
      background: #00f7ff;
      box-shadow: 0 0 5px #00f7ff;
      border-radius: 2px;
      margin-top: 5px;
    }

    .science-block p {
      font-size: 1rem;
      line-height: 1.6;
      color: white;
    }

    .open-link {
      color: #00f7ff;
      text-decoration: none;
      font-weight: bold;
    }

    .open-link:hover {
      text-shadow: 0 0 10px #00f7ff, 0 0 20px #00f7ff;
    }

    table {
  width: 100%;
  max-width: 700px;
  border-collapse: collapse;
  margin: 20px 0;
  color: white;
  text-align: center;
}

    th, td {
      padding: 12px;
      border: 1px solid white;
    }

    th {
      background: #1f1f1f;
    }
    
    .small-text-table {
  font-size: 0.85em;
}

    footer {
  max-width: 700px;
  margin: 0 auto;
  padding: 10px 20px;
  background: #1a1a1a;
  color: white;
  font-size: 0.9rem;
  text-align: center;
}

    #cookieConsent {
      position: fixed;
      bottom: 0;
      width: 100%;
      background: #222;
      color: #fff;
      display: none;
      justify-content: center;
      align-items: center;
      padding: 10px;
      font-size: 0.9rem;
      flex-wrap: wrap;
      gap: 10px;
      z-index: 1000;
    }

    #cookieConsent button {
      padding: 8px 15px;
      background: #f1d600;
      border: none;
      cursor: pointer;
      border-radius: 5px;
    }
  </style>
</head>
<body>
  <header>
    <div class="top-bar">
      <a href="index.html" class="home-brand" aria-label="Finding Dopa Home">
        <i class="fas fa-brain"></i>
        <span class="logo-text">Finding Dopa</span>
      </a>
    </div>
    <div class="slider-container">
      <a href="/dopa/vox.html" class="slide">Dopa VOX</a>
      <a href="news.html" class="slide">Latest News</a>
      <a href="resources.html" class="slide">Resources</a>
      <a href="actors.html" class="slide">The Actors</a>
      <a href="fix-or-cure.html" class="slide">Fix or Cure?</a>
      <a href="science.html" class="slide">The Science</a>
      <a href="clinical-trials.html" class="slide">Clinical Trials</a>
      <a href="about.html" class="slide">About</a>
      <a href="disclaimer.html" class="slide">Disclaimer</a>
    </div>
  </header>

  <div class="main-content">
    <section class="hero-section">
      <img src="images/Clinical-Trials-Disco.jpg" class="hero-img" alt="Parkinson’s Disease Clinical Trials">
    </section>
    <main id="main">
      <section class="intro">
        <p class="hero-line">A fix for Parkinson’s Disease is on the way. Keep fighting!</p>
      </section>

      <div class="science-block">
        <h3>How New Treatments Are Tested</h3>
        <p>Clinical trials are research studies in humans that assess the safety and effectiveness of new treatments. They progress through three phases: Phase 1 tests safety in a small group, Phase 2 evaluates effectiveness and side effects, and Phase 3 confirms results in a larger population. If successful, the treatment may be approved for market use.</p>
      </div>

            <div class="science-block">
        <h3>Phase 1/2 Studies</h3>
        <p>Phase 1/2 trials combine safety (Phase 1) and preliminary efficacy (Phase 2) assessments. Successful trials, like those for bemdaneprocel, may advance to Phase 3 to further evaluate efficacy and safety.</p>
      </div>

            <div class="science-block">
        <h3>Phase 3 Studies</h3>
              <p>Phase 3 trials confirm efficacy and monitor side effects in larger patient populations. Building on Phase 1/2 results, these trials compare the new treatment to standard care, helping determine if it should be approved for widespread use.</p>
              <p>If Phase 3 is conclusive, meaning the treatment shows strong efficacy and acceptable safety, the sponsoring company can submit a marketing authorization application to regulatory agencies (like the FDA in the U.S. or EMA in Europe).</p>
              <p>If approved, the treatment can then be marketed and prescribed to the general public. This is the final step before widespread clinical use—turning a promising therapy into a real-world option for patients.</p>
      </div>

            <div class="science-block">
        <h3>Time to Market</h3>
        <table>
          <thead>
            <tr>
              <th>Step</th>
              <th>Time</th>
            </tr>
          </thead>
          <tbody>
            <tr><td>Preclinical</td><td>1–2 years</td></tr>
            <tr><td>Phase 1</td><td>~1 year</td></tr>
            <tr><td>Phase 2</td><td>~1–2 years</td></tr>
            <tr><td>Phase 3</td><td>~2–4 years</td></tr>
            <tr><td>Regulatory Review</td><td>~6–12 months</td></tr>
            <tr><td><strong>Total</strong></td><td><strong>~6–10 years</strong></td></tr>
          </tbody>
        </table>
      </div>
      
      <div class="science-block">
        <h3>Find Trials</h3>
        <!--<p><strong>exPDite-2</strong>: Phase 3 study evaluating the efficacy and safety of bemdaneprocel, an investigational cell therapy aimed at replacing dopamine-producing neurons. <a href="https://expditestudy.com/?utm_source=brt&utm_medium=referral&utm_campaign=brt_corporate-website&utm_content=eng" class="open-link" target="_blank">Learn More</a></p>/-->
        <p><strong>ClinicalTrials.gov</strong>: Search for worldwide stem cell trials for Parkinson’s disease (recruiting). <a href="https://clinicaltrials.gov/search?cond=Parkinson%20Disease&intr=stem%20cells&aggFilters=status:rec" class="open-link" target="_blank">Search Trials</a></p>
        <p><strong>Fox Trial Finder</strong>: Connect with Parkinson’s research studies based on location and health history. <a href="https://www.michaeljfox.org/trial-finder" class="open-link" target="_blank">Find a Trial</a></p>
        <p><strong>Be Part of Research - NIHR HNS UK</strong>: Current Studies relating to Parkinson's disease. <a href="https://bepartofresearch.nihr.ac.uk/results/search-results?search=%257B%2522facetDef%2522%253A%257B%2522Health%2520Tag%2522%253A%255B%2522Parkinson%27s%2520Disease%2522%255D%252C%2522Study%2520Status%2522%253A%255B%2522Recruiting%2522%255D%257D%257D" class="open-link" target="_blank">See Ongoing Trials</a></p>
        <p><strong>UX-DA001 Study</strong>: Phase 1 exploratory study of UX-DA001, a cell therapy using patient-derived cells to improve motor function. <a href="https://ctv.veeva.com/study/an-exploratory-clinical-study-of-ux-da001-in-subjects-with-idiopathic-parkinsons-disease" class="open-link" target="_blank">Explore Study</a></p>
      </div>
      
                  <div class="science-block">
        <h3>Some Ongoing Trials</h3>
        <table class="small-text-table">
<thead>
  <tr>
    <th>Organization</th>
    <th>Treatment</th>
    <th>Status</th>
  </tr>
</thead>
<tbody>
  <tr>
    <td>BlueRock Therapeutics</td>
    <td>Bemdaneprocel (iPSC-derived dopaminergic neurons)</td>
    <td>Completed Phase I</td>
  </tr>
  <tr>
    <td>Sumitomo Pharma</td>
    <td>CT1-DAP001 (dopaminergic progenitor cells)</td>
    <td>Phase 1/2 (US & Japan)</td>
  </tr>
  <tr>
    <td>Novo Nordisk / Lund Univ.</td>
    <td>NN-9001 (iPSC-derived therapy)</td>
    <td>Phase I</td>
  </tr>
  <tr>
    <td>Aspen Neuroscience</td>
    <td>ANPD001 (autologous iPSC-derived dopamine neurons)</td>
    <td>Phase 1/2a</td>
  </tr>
  <tr>
    <td>iRegene Therapeutics</td>
    <td>NouvNeu001 (early-onset Parkinson’s)</td>
    <td>Phase I</td>
  </tr>
  <tr>
    <td>XellSmart Biomedical</td>
    <td>XS-411 (allogeneic dopaminergic neural progenitors)</td>
    <td>Phase I (US & China)</td>
  </tr>
  <tr>
    <td>S. Biomedics</td>
    <td>iPSC-derived dopaminergic neurons</td>
    <td>Phase I/Ib</td>
  </tr>
  <tr>
    <td>Oryon Cell Therapies</td>
    <td>Autologous iPSC-derived dopamine neurons</td>
    <td>Phase I</td>
  </tr>
  <tr>
    <td>Shanghai Yuesai Biotech</td>
    <td>iPSC-derived dopaminergic neurons</td>
    <td>Phase I</td>
  </tr>
  <tr>
    <td>iCamuno Biotherapeutics</td>
    <td>iPSC-derived dopaminergic neurons</td>
    <td>Phase I</td>
  </tr>
  <tr>
    <td>TreeFrog Therapeutics</td>
    <td>TFG 001 (iPSC-derived therapy)</td>
    <td>Preclinical</td>
  </tr>
  <tr>
    <td>Kenai Therapeutics</td>
    <td>iPSC-derived cell-based therapy</td>
    <td>Preclinical</td>
  </tr>
</tbody>
        </table>
      </div>

<!--   NEW   TRIALS   HERE   -->
      
      <div class="science-block">
        <h3>exPDite-2</h3>
        <p>Bemdaneprocel, a stem cell-derived therapy, is in Phase 3 as of 2025. If successful, it could reach the market by 2027–2028, aiming to restore dopaminergic function in Parkinson’s patients. <a href="https://expditestudy.com/?utm_source=brt&utm_medium=referral&utm_campaign=brt_corporate-website&utm_content=eng" class="open-link" target="_blank">Learn More</a></p>
      </div>

      <div class="science-block">
        <h3>NE3107 / Bezisterim</h3>
        <p>In animal studies, the trial drug showed that the reduction of neuroinflammation led to improved movement, a decrease in the levodopa side effects, as well as a decrease in the loss of brain cells, which means it has the potential to slow disease progression. <a href="https://sunrisepd.com/" class="open-link" target="_blank">Check Here</a></p>
      </div>
      
      <div class="science-block">
        <h3>ASPro-PD</h3>
        <p>The ASPro-PD trial is a world-first phase 3 trial of ambroxol, currently recruiting (2025). <a href="https://clinicaltrials.gov/study/NCT05778617?titles=Nct05778617&rank=1" class="open-link" target="_blank">Clinical Trial NCT05778617 here</a></p>
      </div>

      <div class="science-block">
        <h3>REGENERATE-PD</h3>
        <p>A new gene therapy approach for Parkinson’s disease is being tested in a Phase 2 clinical trial called REGENERATE-PD, which is currently recruiting participants (2025). <a href="https://mytomorrows.com/ask-bio/regenerate-pd/en-us/" class="open-link" target="_blank">Learn more here</a></p>
      </div>

            <div class="science-block">
        <h3>ENERGI-F705PD</h3>
        <p>ENERGI-F705PD is an experimental oral sustained-release medication for Parkinson’s disease. The treatment aims to support overall cellular health rather than just managing symptoms. The therapy recently entered Phase 1 clinical trials in February 2025 with the first patient enrolled.</p>
      </div>

            <div class="science-block">
        <h3>Exenatide-PD3</h3>
        <p>The full results of the Exenatide-PD3 study, a phase 3 clinical trial of Type 2 diabetes drug exenatide (Bydureon), have now been published. They report that the study unfortunately did not meet its primary or secondary endpoints (2025).</p>
      </div>

      <div class="science-block">
        <h3>NET-PD LS-1 Study</h3>
        <p>Concluded in 2013, the NET-PD LS-1 trial (NCT00449865) found that creatine supplementation did not slow Parkinson’s progression compared to placebo. Results were published in 2015.</p>
      </div>

    </main>
  </div>

  <footer>
    © 2025 Finding Dopa. All rights reserved.
  </footer>

  <div id="cookieConsent">
    This website uses cookies to enhance your experience.
    <button onclick="handleConsent(true)">Accept</button>
    <button onclick="handleConsent(false)">Decline</button>
  </div>

  <script>

    // Highlight active menu item
    const currentPage = window.location.pathname.split("/").pop();
    const slides = document.querySelectorAll('.slider-container .slide');
    slides.forEach(slide => {
      if (slide.getAttribute('href') === currentPage) {
        slide.classList.add('active');
      }
    });
    
    function handleConsent(consent) {
      localStorage.setItem("cookiesAccepted", consent);
      document.getElementById("cookieConsent").style.display = "none";
      if (consent) loadAnalytics();
    }

    function loadAnalytics() {
      console.log("Analytics loaded");
    }

    window.onload = function() {
      const consent = localStorage.getItem("cookiesAccepted");
      if (consent === null) {
        document.getElementById("cookieConsent").style.display = "flex";
      } else if (consent === "true") {
        loadAnalytics();
      }
    };
  </script>
</body>
</html>
